Trial Profile
A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs S 095033 (Primary) ; Docetaxel; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Cholangiocarcinoma; Lymphoma; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Agios Pharmaceuticals
- 22 Jun 2023 Status changed from completed to discontinued.
- 02 May 2023 Status changed from active, no longer recruiting to completed.
- 29 Jul 2022 Status changed from recruiting to active, no longer recruiting.